Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching ; volume:38 ; number:3 ; day:23 ; month:3 ; year:2024 ; pages:331-339 ; date:5.2024
BioDrugs ; 38, Heft 3 (23.3.2024), 331-339, 5.2024
- Urheber
-
Cohen, Hillel P.
Bodenmueller, Wolfram
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-024-00655-4
- URN
-
urn:nbn:de:101:1-2407111545570.722572464412
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cohen, Hillel P.
- Bodenmueller, Wolfram
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Statistical topics in clinical biosimilar development
Correction to: AVT04: An Ustekinumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Statistical topics in clinical biosimilar development
Correction to: AVT04: An Ustekinumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Statistical topics in clinical biosimilar development